Global Leading Market Research Publisher QYResearch announces the release of its latest report “Influenza A/B Nucleic Acid Detection Kit – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global influenza A/B nucleic acid detection kit market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for influenza A/B nucleic acid detection kit was estimated to be worth US234millionin2025andisprojectedtoreachUS234millionin2025andisprojectedtoreachUS 328 million, growing at a CAGR of 5.0% from 2026 to 2032. This sustained growth is driven by the annual seasonal burden of influenza (resulting in 3-5 million severe cases and 290,000-650,000 respiratory deaths globally), the expansion of influenza surveillance networks following the COVID-19 pandemic, increasing adoption of molecular diagnostics for rapid and accurate viral identification, and the growing integration of multiplex respiratory panels that include influenza alongside SARS-CoV-2, RSV, and other pathogens.
The influenza A/B nucleic acid detection kit is an in vitro diagnostic reagent set based on nucleic acid amplification technology, enabling specific identification, amplification, and detection of Influenza A and B virus nucleic acids in samples for rapid determination of corresponding viral infections. These PCR testing kits typically utilize reverse-transcription real-time PCR (RT-qPCR) or isothermal amplification methods to detect viral RNA extracted from nasopharyngeal swabs, oropharyngeal swabs, or nasal aspirates. Compared to rapid antigen tests (sensitivity 50-70%), molecular influenza detection offers significantly higher sensitivity (95-99%) and specificity (98-100%), enables subtyping of influenza A (e.g., H1N1, H3N2), and remains the gold standard for laboratory confirmation of influenza infection in clinical and public health settings.
For comprehensive market segmentation, packaging configuration comparisons, and application-specific intelligence, industry stakeholders can access the complete dataset.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6092873/influenza-a-b-nucleic-acid-detection-kit
Market Segmentation by Packaging Format and End-User
The influenza A/B nucleic acid detection kit market is segmented as below to reflect distinct testing volumes and operational settings:
Selected Key Players (Partial List):
Certest Biotec, Diagnostica Longwood, MIZUHO MEDY, QIAGEN, DNA-Technology, FLASHTEST Technology, Xi’an Tianlong Science and Technology Co., Ltd, Shanghai ZJ Bio-Tech Co., Ltd., Jiangsu Mole Bioscience Co., Ltd., Coyote Bioscience Co., Ltd., Zybio Inc.
Segment by Packaging Format
- 32 Test/Box – Smaller batch size; ideal for smaller hospitals, clinics, and low-volume seasonal testing
- 96 Test/Box – Standard microplate format; compatible with standard real-time PCR instruments; preferred for medium-to-high volume laboratories
- Other Packaging Specifications (e.g., 48-test, 24-test, ready-to-use lyophilized single tubes for point-of-care)
Segment by End-User
- Hospital (clinical virology laboratories, emergency departments, infectious disease wards)
- CDC (public health surveillance, outbreak response, seasonal influenza monitoring)
- Third-party Testing Agency (reference laboratories, corporate wellness screening, travel health services)
Technical Deep Dive: PCR-Based Influenza Detection and Assay Design Considerations
A critical technical consideration in selecting an influenza A/B nucleic acid detection kit is the target gene region and amplification chemistry. Most commercial kits target conserved regions of the influenza A matrix protein (M) gene or the nucleoprotein (NP) gene, and influenza B matrix or hemagglutinin (HA) genes, often with separate FAM/HEX dye channels or multiplexed single-well detection. Assay sensitivity, expressed as limit of detection (LoD), typically ranges from 500-5,000 copies/mL for reliable detection, with high-performance kits achieving 100-500 copies/mL. The 2025-2026 influenza season (Northern Hemisphere) saw co-circulation of A(H1N1)pdm09, A(H3N2), and both Victoria and Yamagata lineage B viruses, underscoring the importance of kits that detect all circulating strains without cross-reactivity.
A notable technical challenge for molecular diagnostics of influenza is the emergence of genetic variants that can cause primer-probe mismatches. During the 2024-2025 season, a novel H3N2 clade (3C.3a) with amino acid substitutions near the primer binding region of the NP gene led to reduced detection efficiency in three commercial kits (approximately 15-20% signal reduction compared to reference strains). In response, manufacturers including QIAGEN and Xi’an Tianlong Science and Technology updated their influenza A detection primer designs for the 2025-2026 season, a process now accelerated by real-time global sequence surveillance through platforms such as GISAID and WHO’s GISRS.
Another critical differentiation among influenza A/B nucleic acid detection kits is the internal control strategy. Most kits include an internal control (typically human RNase P or beta-globin gene) co-amplified in a separate fluorescent channel to monitor sample adequacy, extraction efficiency, and PCR inhibition. Dual-target internal controls (e.g., spiked synthetic RNA + human gene) offer superior performance but increase kit complexity and cost. Manufacturers serving high-volume laboratories (QIAGEN, Certest Biotec) generally provide Comprehensive Quality Control including positive and negative control materials, while smaller-format kits (32-test, some 48-test) may omit external controls to reduce per-test cost.
The shift toward lyophilized (freeze-dried) and room-temperature stable PCR reagents has been a significant recent innovation. In October 2025, Jiangsu Mole Bioscience launched a 96-test influenza A/B nucleic acid detection kit with lyophilized master mix in individual tubes, eliminating cold chain requirements (-20°C storage reduced to 2-8°C or room temperature) and reducing degradation risk in low-resource settings. However, lyophilized kits typically have higher per-unit manufacturing costs, resulting in 10-20% price premiums over liquid formulations.
Recent Market Developments and Regional Dynamics
The influenza A/B nucleic acid detection kit market has experienced significant developments in 2025-2026. In December 2025, the WHO Global Influenza Strategy (2026-2031) was released, emphasizing expanded molecular surveillance capacity in low- and middle-income countries, including procurement of respiratory diagnostic reagents through the WHO Global Influenza Surveillance and Response System (GISRS). This strategic direction is expected to drive kit procurement for public health surveillance, particularly for 96-test formats compatible with existing global laboratory networks.
In January 2026, the FDA granted Emergency Use Authorization (EUA) for a combined Influenza A/B + SARS-CoV-2 + RSV multiplex nucleic acid detection kit (MIZUHO MEDY’s Respi-4plex), reflecting the post-pandemic consolidation of respiratory testing into single-tube multiplex panels. Similar combined kits from Shanghai ZJ Bio-Tech and Coyote Bioscience have received NMPA approval in China. This multiplexing trend reduces per-test costs (3-5 analytes for 1.2-2.5x price of single-plex) and preserves patient specimens, but presents technical challenges in assay design (balancing amplification efficiency across targets, preventing cross-reactivity).
Regional market dynamics reveal that North America accounts for approximately 40% of influenza A/B nucleic acid detection kit demand, driven by robust seasonal testing volume (CDC estimates 35-50 million influenza episodes annually requiring 5-10 million molecular tests) and large installed base of real-time PCR instruments. Europe represents 30%, with Germany, France, Italy, and the UK as major markets. Asia-Pacific is the fastest-growing region (CAGR 7-9%), driven by expanding hospital diagnostic capacity in China (an estimated 3,200+ hospitals with molecular testing capability as of 2025), India (expansion of flu surveillance under Integrated Disease Surveillance Programme), and Japan (seasonal testing under National Epidemiological Surveillance of Infectious Diseases). Chinese manufacturers (Xi’an Tianlong, Shanghai ZJ Bio-Tech, Jiangsu Mole Bioscience) have gained significant domestic market share through competitive pricing (30-50% below imported equivalents) and NMPA approvals for locally circulating strains.
Industry Sub-segment Divergence: Hospital vs. CDC vs. Third-party Testing Agency Applications
The influenza A/B nucleic acid detection kit market divides meaningfully across three end-user segments. Hospital clinical virology laboratories (approximately 50% of demand) prioritize rapid turnaround (same-day results for clinical management decisions), ease of use for multi-shift medical technologists, and integration with hospital information systems. These customers typically use PCR testing kits that are compatible with their existing real-time PCR platforms and prefer 96-test box formats for cost efficiency. Seasonal demand creates significant inventory management challenges; hospitals typically stock 2-4 weeks of kit supply during peak season (December-February in Northern Hemisphere) and minimal inventory during inter-seasonal periods.
CDC and public health laboratories (approximately 25% of demand) prioritize subtyping or strain identification beyond simple A/B differentiation (often using additional kits or sequencing), high sensitivity for surveillance of low-prevalence strains, and compatibility with standardized WHO testing protocols. These customers often use multiple influenza detection formats including 96-test kits for seasonal surveillance and smaller packaging (32-test) for outbreak investigations. Public health purchasing is often centralized through government tenders with rigorous validation requirements.
Third-party testing agencies and reference laboratories (approximately 25% of demand) prioritize per-test cost optimization, high-throughput compatibility (often using 96-well or 384-well formats with automated liquid handling), and broad test menu including multiplex respiratory panels. These customers typically have the most diverse instrumentation fleets and may require kit flexibility across multiple thermocycler brands. A distinctive exclusive observation: the post-pandemic surge in workplace wellness testing (corporate screening, travel health, pre-event surveillance) has created demand for influenza A/B nucleic acid detection kits in non-traditional laboratory settings. The 2025-2026 season saw 18% growth in kit sales to occupational health providers (e.g., companies offering on-site or near-site employee testing), driving demand for smaller packaging formats (32-test or lower) and simplified workflows suitable for non-clinical laboratory personnel.
Future Outlook and Strategic Recommendations
As the influenza A/B nucleic acid detection kit market evolves toward 2032, three strategic directions emerge: (1) continued consolidation into multiplex respiratory panels (5-15 targets), reducing the need for single-plex influenza-only testing except in resource-limited settings; (2) expansion of point-of-care molecular influenza tests with integrated sample-to-answer systems (e.g., Cepheid GeneXpert, Roche Liat, Abbott ID NOW) driving demand for proprietary cartridge-based molecular diagnostics while reducing demand for open-system PCR kits; and (3) adoption of isothermal amplification (LAMP, RPA, NEAR)-based kits that reduce instrument requirements and enable detection in lower-resource settings. For hospital laboratories, selecting an influenza A/B nucleic acid detection kit compatible with existing PCR instruments, offering strong performance against currently circulating strains, and providing flexible packaging options (both 32-test and 96-test) optimizes both routine and surge capacity management. For CDC and public health laboratories, prioritizing strain coverage, high sensitivity for low-prevalence detection, and compatibility with WHO reference protocols is essential. For respiratory diagnostic manufacturers, differentiation will increasingly come from multiplexing capability (flu plus SARS-CoV-2, RSV, hMPV, adenovirus), lyophilized room-temperature stable formulations, and rigorous strain-tracking with rapid primer-probe update mechanisms. By 2030, it is anticipated that influenza A/B-only detection kits will represent less than 50% of the molecular influenza detection market in high-income countries, as multiplex panels become standard for respiratory testing, but will remain significant in low- and middle-income countries and for targeted surveillance applications.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
